News

• 2025-08-29

  Nature Medicine Publishes a Breakthrough! Experts highly praise

  A major step forward for off-the-shelf cell therapy in autoimmunity. Prof. Huji Xu, Prof. Xin Lin, and BriSTAR Immunotech are breaking new ground with YTS109, a hypoimmune allogeneic T cell product. Published in Nature Medicine:

• 2025-08-28

  Landmark Study Published in Nature Medicine: BriSTAR Immunotech’s Allogeneic STAR-T Breaks New Ground in Refractory Lupus Nephritis Treatment

  On August 27, 2025, a groundbreaking study by BriSTAR Immunotech in collaboration with the team led by Professor Huji Xu and Professor Xin Lin , was published in the top international journal Nature Medicine (Impact Factor: 58.7).

• 2024-11-18

  Professor Lin Xin's Team Publishes Landmark Research in Cell Sub-Journal: STAR-T Technology Enables Targeting of Intracellular Neoantigens for Solid Tumor Therapy

  Recently, a team led by Professor Xin Lin — Scientific Founder of Bristar Immunotech and Tenured Professor at Tsinghua University — published a research article titled "TCR-mimicking STAR conveys superior sensitivity over CAR in targeting tumors with low-density neoantigens" in Cell Reports, a sub-journal of Cell. This study demonstrates the high sensitivity of the novel chimeric antigen receptor STAR-T in targeting tumors with low-abundance neoantigens, promising to advance T-cell immunotherapy into an era of greater precision and efficacy. It also marks another breakthrough in STAR-T technology research.